• Measure Summary
  • NQMC:011141
  • 2015 Mar

Hepatopancreatobiliary (HPB) cancer: proportion of patients with hepatocellular carcinoma (HCC) undergoing disease specific treatment (liver transplant, resection, ablation, trans-arterial chemoembolisation [TACE] or systemic anti-cancer therapy [SACT]) who die within 30 days of definitive treatment.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011121
  • 2016 May

Sarcoma: proportion of patients with osteosarcoma who are under the age of 40 who undergo neo-adjuvant combination systemic anti-cancer therapy (SACT).

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011264
  • 2016 Feb

Cutaneous melanoma: proportion of patients with cutaneous melanoma who undergo diagnostic excision biopsy where the surgical pathology report contains a full set of data items (as defined by the current Royal College of Pathologists dataset).

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011016
  • 2017 Feb

Non-Hodgkin lymphoma: percent of lymphoma patients of childbearing age who received treatment for lymphoma and who were offered fertility counseling prior to starting treatment OR documentation in the medical record why such counseling was unnecessary.

American Society of Hematology

  • Measure Summary
  • NQMC:011174
  • 2016 Nov

Melanoma: percentage of patients, regardless of age, with a current diagnosis of stage 0 through IIC melanoma or a history of melanoma of any stage, without signs or symptoms suggesting systemic spread, seen for an office visit during the one-year measurement period, for whom no diagnostic imaging studies were ordered.

American Academy of Dermatology; National Committee for Quality Assurance; Physician Consortium for Performance Improvement®

  • Measure Summary
  • NQMC:011069
  • 2016 Jun

Bladder cancer: proportion of patients with muscle invasive bladder cancer (MIBC) who are discussed at the multidisciplinary team (MDT) meeting before definitive treatment.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:010967
  • 2016 Sep

Upper gastrointestinal (UGI) endoscopy: percentage of patients monitored for complications (adverse events) after therapeutic UGI endoscopy.

European Society of Gastrointestinal Endoscopy

  • Measure Summary
  • NQMC:011054
  • 2017 Jun
  • NQF-Endorsed Measure

Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer at low (or very low) risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer.

American Medical Association; American Urological Association

  • Measure Summary
  • NQMC:011038
  • 2016 Jan

Ovarian cancer: proportion of patients with stage 1 epithelial ovarian cancer having Risk of Malignancy Index (RMI) assessed and recorded in their notes prior to any definitive surgical intervention.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011155
  • 2016 Jun

Testicular cancer: proportion of patients with stage I seminoma receiving adjuvant single dose carboplatin area under the curve of 7 mg/ml/min (AUC7), based on ethylene diamine tetra-acetic acid (EDTA) clearance, within 8 weeks of orchidectomy.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011231
  • 2017 Feb

Lung cancer: proportion of patients with non small cell lung cancer (NSCLC) who receive curative treatment (radical radiotherapy, radical chemoradiotherapy or surgical resection) who undergo PET CT prior to start of treatment.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011191
  • 2015 Sep

Lymphoma: proportion of patients with nodal, non-bulky stage 1a diffuse large B-cell lymphoma (DLBCL) who receive local radiotherapy, in combination with chemotherapy.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011158
  • 2016 Jun

Testicular cancer: proportion of patients with stage I testicular non-seminomatous (or mixed) germ cell tumour (NSGCT) who undergo at least three CT scans of the abdomen +/- chest and pelvis within 14 months of diagnosis.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011175
  • 2016 Aug

Cervical cancer: proportion of patients with cervical cancer who have an MRI of the pelvis performed prior to definitive treatment.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011267
  • 2016 Feb

Cutaneous melanoma: proportion of patients with cutaneous melanoma who undergo sentinel node biopsy (SNB) where the SNB report contains a full set of data items (as defined by the current Royal College of Pathologists dataset).

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011138
  • 2015 Mar

Hepatopancreatobiliary (HPB) cancer: proportion of patients with hepatocellular carcinoma (HCC) undergoing either CT or MRI and with full information recorded.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011013
  • 2017 Feb

Non-Hodgkin lymphoma: percent of lymphoma patients assigned a specific stage using Ann Arbor system including presence/absence of B symptoms AND having bone marrow biopsy or documentation why bone marrow biopsy was unnecessary or contraindicated.

American Society of Hematology

  • Measure Summary
  • NQMC:011124
  • 2016 May

Sarcoma: proportion of patients with sarcoma who undergo surgical resection or oncological treatment with curative intent who die within 30 days of treatment.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011210
  • 2016 Jul

Prostate cancer: proportion of patients with prostate cancer who are enrolled in an interventional clinical trial or translational research.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:010918
  • 2016 May

Cervical cancer screening: percentage of Pap tests with an HSIL+ result that have a histological confirmation of HSIL, carcinoma in situ, or invasive carcinoma within 12 months of the HSIL+ Pap test.

Canadian Partnership Against Cancer; Public Health Agency of Canada